QuantAbundanciaAbundância, quantificada.

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

23,576 signal articles · 340 in last 24h · 112,338 total before filter · latest 31m ago
340last 24h
2149last 7d
376● bullish (7d)
189● bearish (7d)
204publishers
AllMacro296Earnings1222M&A90Regulatory23Product13Analyst20
✕ clear all filtersticker: GSsentiment: bullishSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Goldman Sachs to Buy Neos Investments for $2.25 Billion
Bloomberg15h agobullishVIDEO
Goldman Sachs to Buy Neos Investments for $2.25 Billion

Goldman Sachs Group will pay as much as $2.25 billion to buy Neos Investments, expanding its asset manager's reach in the actively managed ETF market. Katherine Doherty reports on "Bloomberg Open Interest."

Nvidia Confirms Huge AI Funding Deal. These Financial Stocks Jump.
Investor's Business Daily2d agobullish
Nvidia Confirms Huge AI Funding Deal. These Financial Stocks Jump.

Nvidia confirmed on Monday that it will partner with some of the world's largest financial companies on a $500 billion financing effort to build out artificial intelligence infrastructure. Nvidia will work with Apollo Global Management, Blackstone and Goldman Sachs "to mobilize over $500 billion of third-party capital for the buildout of AI infrastructure over time," a news release said.

Bloomberg5d agobullish
Non-Opioid Painkiller Maker Latigo Jumps 17% After Upsized IPO

(Bloomberg) -- Latigo Biotherapeutics Inc., a clinical-stage developer of non-opioid pain medicines, climbed 17% on Friday after raising $345.6 million in an upsized initial public offering, priced at the top of a marketed range.Most Read from BloombergOpenAI’s New Device Will Be Hockey Puck-Sized and Cost Over $300Iran Wants to Bar US, Israeli Ships From Hormuz in Peace AccordIran Says Agreement on Hormuz Shipping Reached With OmanTrump Administration Considers Order on Autism and VaccinesWhy D

Goldman Sachs (GS) Premium Income ETFs Are Beating JPMorgan On Yield And Returns
Simply Wall St.9d agobullish
Goldman Sachs (GS) Premium Income ETFs Are Beating JPMorgan On Yield And Returns

Goldman Sachs Group (NYSE:GS) premium income ETFs, GPIX and GPIQ, are currently outperforming JPMorgan’s JEPI and JEPQ across expense ratios, dividend yields, and total returns. The comparison highlights competitive advantages for Goldman Sachs products in the premium income ETF category. The performance gap has drawn attention to Goldman Sachs as a growing player in retail income-focused ETFs. Goldman Sachs Group has long been known for its institutional and advisory businesses, and its...

Bloomberg9d agobullish
Dip Buyers Need to Heed the Market’s Warning Signs

(Bloomberg) -- The momentum trade just gave investors a taste of the pronounced profit-and-loss swings they can expect if they fail to hedge or diversify, a warning that’s reinforced by growing inflation risks. Most Read from BloombergTrump Says US to Hold Off Iran Attack If Deal AgreedSaudi Prince Concerned Over Trump’s Iran Strike Plan: AxiosTrump Says Iran Talks to Begin Monday After Scrapping AttackSingapore's Gated Island for the Rich Is Marred by Decayed HomesAlibaba Adds to China AI Break

Goldman Sachs (GS) Launches Private Markets Platform And Buys AEGIS Hedging Solutions
Simply Wall St.18d agobullish
Goldman Sachs (GS) Launches Private Markets Platform And Buys AEGIS Hedging Solutions

Goldman Sachs Group (NYSE:GS) has launched a new private markets platform aimed at wealthy clients, expanding access to alternative investments. Goldman Sachs Alternatives has agreed to acquire AEGIS Hedging Solutions, a provider of risk management and hedging services. For investors watching how Goldman Sachs Group positions itself beyond traditional investment banking, these two moves sit squarely in its asset and wealth management efforts. A broader private markets platform for high net...

Bloomberg19d agobullish
Eli Lilly-Backed Scribe Therapeutics Jumps 67% After Upsized IPO

(Bloomberg) -- Scribe Therapeutics Inc., a clinical-stage developer of gene therapies for heart diseases, surged 67% on Friday after raising $128.7 million in an upsized initial public offering.Most Read from BloombergRetina Chip Designed to Restore Sight to Go on Sale in EuropeHegseth Turns to UNC, Virginia Tech After Dropping Ivy LeagueApple Plans Overhaul of MacBooks, iMac in Push to Meet AI DemandTrump Rebuilds Tariffs With New Levies on 60 EconomiesSpaceX Turns Away Falcon Customers in Majo

The Bull Case For Goldman Sachs Group (GS) Could Change Following Record Q2 Earnings And Bigger Buybacks
Simply Wall St.20d agobullish
The Bull Case For Goldman Sachs Group (GS) Could Change Following Record Q2 Earnings And Bigger Buybacks

Earlier in July 2026, Goldman Sachs reported strong second-quarter results, with net income rising to US$6.63 billion and earnings per share roughly doubling year-on-year. Alongside these results, Goldman Sachs intensified capital return and funding actions, including billions in new bond and preferred issuances plus continued buybacks and a higher quarterly dividend. We’ll now examine how this combination of record earnings and increased capital returns might influence Goldman Sachs’...

Bloomberg22d agobullish
Wall Street Talks Up Carry Trade as Returns Soar Most in Decades

(Bloomberg) -- One of the most enduring foreign-exchange bets is off to its best run in decades as surprisingly muted volatility across asset classes has investors piling into carry trades.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Campaign After Troo

Bloomberg25d agobullish
China’s Moonshot Plans IPO in Six Months After AI Breakthrough

(Bloomberg) -- Moonshot AI has told investors it’s preparing to list in as early as six months, seizing the opportunity to tap capital markets after its latest model upended industry perceptions of China’s burgeoning capabilities and sent global tech stocks reeling.Most Read from BloombergFCC Near Rulings Against Disney Over ‘The View,’ TV LicensesUS Strikes Iran to ‘Punish’ It for Attack That Killed 2 TroopsThousands of Trucks Haul Iraq’s Oil Through Syria in Sign of Hormuz LegacyTaylor Farms P